Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07056075

Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP

Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory/airway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and/or monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.

For this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring/treatment (i.e., 2 L O2/min via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 <85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Division of Gastroenterology and Hepatology, Department of Medicine, Medical University Graz, Graz, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • undergoing an interventional (intent) ERCP procedure
  • 18-99 years
  • Male or female
  • Nurse-administered sedation

Exclusion criteria

  • History of allergic reaction to Propofol
  • Tracheostomy
  • Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge
  • Pregnant patients

Treatment and study plan

Nasal PAP Ventilation System

Device

medical devices that provide nasal positive airway pressure ventilation during endoscopy

Other names: nasal positive airway pressure

Low flow oxygen

Device

low flow oxygen though nasal cannula

Capnometry

Device

capnometry measurement

Primary outcomes

  1. Difference in desaturation rate

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Differences of rates of desaturations (i.e., SpO2 <85% for any duration) of the PAP group vs. the standard management group

Secondary outcomes

  1. Difference in desaturation rate

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Differences of rates of desaturations (i.e., SpO2 <85% for any duration) across the three groups

  2. Difference in desaturation rate

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Differences of rates of desaturations (i.e., SpO2 <85% for any duration) of the capnometry group vs. the standard management group

  3. Difference in desaturation rate

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Differences of rates of desaturations (i.e., SpO2 <85% for any duration) of the PAP group vs. the capnometry group

  4. Rates of interventions for hypoxemic events

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Rates of interventions for hypoxemic events in the PAP group vs. the control group

  5. Rates of interventions for hypoxemic events

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Rates of interventions for hypoxemic events in the PAP group vs. the capnometry group

  6. Rates of interventions for hypoxemic events

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Rates of interventions for hypoxemic events in the capnometry group vs. the control group

  7. Lowest SpO2

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Lowest SpO2 values across the three groups

  8. Median procedure length

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Median procedure length (min) across the three groups

  9. Satisfaction with sedation

    Time frame: Periprocedural

    Endoscopist and patient satisfaction levels concerning the procedure on a Likert scale ("Satisfaction scale" 0-10, 0=worst, 10=best) across the three groups

  10. Rate of sedation-related adverse events

    Time frame: during endoscopic retrograde cholangio-pancreatography

    Rate of sedation-related adverse events across the three groups

  11. Rate of SCOPE

    Time frame: from ERCP up to 30 days after procedure

    Rate of a combined endpoint of serious adverse events and clinical outcomes (SCOPE) across the three groups

    SCOPE (serious adverse events and clinical outcomes in procedural endoscopy) includes:

    30-day all-cause mortality, cardiopulmonary resuscitation1, unplanned intubation or non-invasive ventilation1, single or multiorgan dysfunction due to an endoscopy-related adverse event (AGREE IVa/IVb), rescue or secondary intervention (endoscopic, surgical, or interventional radiology) due to an endoscopy-related adverse event (AGREE IIIa/b), post-ERCP pancreatitis, or target not reached (with necessity of a secondary procedure)

    1 AE occurring after start of the procedure (first dose of sedation administered) until patient leaves recovery room.

Sponsors and collaborators

Lead sponsor

Karl Landsteiner University of Health Sciences

Other

Registry information

Official study title

A Randomized, Controlled, Unblinded Trial Evaluating the Impact of Positive Airway Pressure and Capnometry Compared to Standard Management on the Rate of Desaturations During Nurse-administered Sedation ERCP

Acronym: PrePAP-ERCP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 9, 2025
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.